Evidence map›Paper›PMID 35839444›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.

Catalina Amador, Alyssa Bouska, George Wright, Dennis D Weisenburger, Andrew L Feldman, Timothy C Greiner, Waseem Lone, Tayla Heavican, Lynette Smith, Stefano Pileri and 28 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Failing Forward in Peripheral T-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 9 countries.

Catalina AmadorDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-0352-5526
Alyssa BouskaDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
George WrightBiometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Dennis D WeisenburgerDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN.
Timothy C GreinerDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-1470-8328
Waseem LoneDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Tayla HeavicanDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0002-8384-6217
Lynette SmithDepartment of Biostatistics, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0002-0836-9932
Stefano PileriEuropean Institute of Oncology, Milan/Bologna University School of Medicine, Bologna, Italy.ORCID 0000-0001-8032-5128
Valentina TabanelliEuropean Institute of Oncology, Milan/Bologna University School of Medicine, Bologna, Italy.ORCID 0000-0002-4142-2248
German OttDepartment of Clinical Pathology, Robert-Bosch Krankenhaus and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.ORCID 0000-0001-7990-6793
Andreas RosenwaldInstitute of Pathology, University of Wurzburg, and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany.
Kerry J SavageCenter for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.ORCID 0000-0002-5835-9863
Graham SlackCenter for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
Won Seog KimSungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-5400-0466
Young HyehSungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-4383-0579
Yuping LiDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Gehong DongDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Joo SongDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0003-3497-2513
Sarah OndrejkaPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0001-9431-2889
James R CookPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-0456-8085
Carlos BarrionuevoDepartamento de Patologia Instituto Nacional de Enfermedades Neoplásicas, Facultad de Medicina Universidad Nacional Mayor de San Marcos, Lima, Peru.
Soon Thye LimDivision of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-0366-5505
Choon Kiat OngDivision of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0001-6402-4288
Jennifer ChapmanDepartment of Pathology, University of Miami, Miami, FL.
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weil Cornell Medical College, New York, NY.ORCID 0000-0001-5566-0864
Philipp W RaessDepartment of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0002-6841-4993
Sharathkumar BhagavathiDepartment of Pathology, University of Iowa, Iowa, IA.
Clare GouldPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0002-3043-9503
Piers BlomberyPeter MacCallum Cancer Centre, Melbourne, Australia.
Elaine JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-4632-0301
Stephan W MorrisHealthchart, LLC, Memphis TN.
Lisa M RimszaDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Scottsdale, AZ.
Julie M VoseDivision of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-1015-7434
Louis StaudtMetabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.ORCID 0000-0002-6243-6008
Javeed IqbalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-3668-0629
University of Nebraska Medical Center · USCity Of Hope National Medical Center · USBC Cancer Agency · CACleveland Clinic · USDuke-NUS Medical School · SGEuropean Institute of Oncology · ITNational Institutes of Health · USPeter MacCallum Cancer Centre · AUSungkyunkwan University · KRBeijing Tongren Hospital · CNCornell University · USMayo Clinic · USMayo Clinic in Arizona · USNational Cancer Institute · USNational University of San Marcos · PEOregon Health & Science University · USRobert Bosch Hospital · DEUniversity of Iowa · USUniversity of Miami · USUniversity of Würzburg · DE

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Molecular diagnosis and outcome prediction in lymphomaZIABC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0M
Preclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI SCOTT, DAVID WILLIAM · 2018 to 2022
$10.2M
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesisR01CA251412 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IQBAL, JAVEED, SONG, JOO · 2021 to 2025
$2.4M
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signaturesU01CA253218 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IQBAL, JAVEED, MURTAZA, MUHAMMED · 2021 to 2025
$1.8M
Molecular diagnostic and prognostic signatures for PTCLUH3CA206127 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHAN, WING C., IQBAL, JAVEED · 2019 to 2021
$864k
Molecular diagnostic and prognostic signatures for PTCLUH2CA206127 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHAN, WING C., IQBAL, JAVEED · 2017 to 2018
$397k
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)R41CA221466 · NCI · HEALTHCHART, LLC · PI CHAN, WING C., IQBAL, JAVEED · 2018 to 2018
$299k
NCI NIH HHS P01 CA229100NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA251412NCI NIH HHS R41 CA221466NCI NIH HHS U01 CA253218NCI NIH HHS UH2 CA206127NCI NIH HHS UH3 CA206127
6 · The paper itself

Abstract

purposePeripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression-based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND

methodsWe assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays.

resultsIn the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen-derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners.

conclusionWe developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.

Indexed as

Lymphoma, T-Cell, PeripheralGene Expression ProfilingHumansPrognosisReproducibility of ResultsTranscriptome

Identifiers

PMID35839444
PMCPMC9916147
OpenAlexW4285491618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.